We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
It appears the street didn't care for this news. Checking Zacks I see where mgt missed annual expectations (actual: -1.66, estimate: 1.60), and last qtr (actual: -.49, estimate: -.43). Other news sounds OK.
Some comments from H&Q (www.hamquist.com) on EVTI::
EVT is developing the first less-invasive procedure for the repair of abdominal aortic aneurysms (AAAs) with an estimated one-year lead over the nearest competitor, Medtronic.
A less-invasive approach to AAA repair offers at least a 50% reduction in death and complications, faster recovery, and lower cost versus the traditional open procedure.
EVT has completed pivotal trials for the first two versions of the product, with excellent short-term results on the first and data due on the second in May or June 1997.
EVT has received CE Mark approval, and is currently initiating full-scale launch in Europe.
Visibility on competition is high because barriers to entry are relatively high, with a minimum of four years from concept to launch; two products are in U.S. clinical trials, but many others are on the drawing board.
EVT is clearly a takeover play; its new relationship with Guidant appears to indicate high interest from the company, the major player with the greatest need for EVT's product.
Our 12-month price target is $15, and our 18-month target is $20 with value generated by greater visibility on Pre-Market Approval (PMA) submission and EVT's lead to market.